Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Vaginal, Placental and Neonatal Buccal Mycobiota and Microbiome in Preterm Birth

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04165252
Recruitment Status : Not yet recruiting
First Posted : November 15, 2019
Last Update Posted : November 15, 2019
Sponsor:
Collaborator:
Tubitak
Information provided by (Responsible Party):
Koç University

Brief Summary:

Microbiota contributes to the immunological, hormonal and metabolic homeostasis of the host. As in all natural orifices in the body, there is also a microbiota and mycobiota specific to the vagina.

On the other hand, the sonographic short cervix in the second trimester of pregnancy is associated with preterm delivery, which may be an important cause of mortality and morbidity in the neonatal period. American Society of Obstetricians and Gynecologists (ACOG), British Royal Society of Obstetricians and Gynecologists (RCOG) and the American Society of Maternal Fetal Medicine (SMFM) suggest that the measurement of transvaginal sonographic cervical length at 20-24 gestational weeks for the screening of preterm birth. The aforementioned associations also recommend the use of progesterone in the treatment of women who diagnosed with short cervix by transvaginal ultrasonography due to the fact that progesterone is an effective medication in the prevention of preterm birth (Grade B).

Previous vaginal microbiota studies have shown that some bacterial species such as Lactobacillus insers cause a predisposition to premature labor in women with a short cervix. However, the prominent lack in these studies is that the eukaryotic fungi in abundant vaginal flora have not been evaluated.

On the other hand, it was already shown that progesterone treatment is able to prevent only 45% preterm birth in women with short cervical length. This observational prospective study thus aims to evaluate the variety of microbiota and/or mycobiota in pregnancies resulting in preterm birth and those who give birth at term. Although women with short cervical length receive progesterone regularly from the second trimester, the preterm birth may occur. In this study, the investigators also aim to evaluate the patterns of microbiota and mycobiota from vaginal swabs of women who had preterm birth with short cervical length and postpartum swabs of the placenta and fetal oral cavity.


Condition or disease Intervention/treatment
Preterm Birth Microbial Colonization Diagnostic Test: Collection of vaginal, neonatal buccal and placental samples

Detailed Description:

Preterm birth is responsible for more than 70% of all neonatal and infant deaths. In addition, the risk of cerebral palsy among children born preterm is 10 times than those born at term. The risk of preterm birth is inversely related to cervical length at midgestation. Randomized-controlled trials involving singleton pregnancies with a short cervical length ( less than 25 mm) have shown that the prophylactic use of progesterone significantly decrease the rate of preterm delivery and neonatal death. The relation of vaginal micobiota with preterm birth has been documented. Yet, impact of short cervical lenght and progesteron treatment on vaginal, neonatal and placental microbiota and mycobiota has not been evaluated. The objectives of present study are to adress the following points;

  1. Longitudinal maternal (vaginal), fetal (oral) and placental (basal plate and parenchyma) 16S-based and 18S-based metagenomic profiling with inferred metagenomics will reveal distinct microbial communities in association with preterm birth.
  2. Comparison of vaginal, neonatal (buccal) and placental (basal plate and parenchyma) 16s rRNA with bacteria and 18s rRNA with fungi in pregnant women with a short cervical length with those with normal cervical length;

2. Comparison of maternal (vaginal), neonatal(oral) and placental (basal plate and parenchyma)16s rRNA with bacteria and 18s rRNA with fungi in pregnant women with short cervical length who gave a preterm birth with those who gave birth at term; 3. The effect of progesterone on maternal (vaginal), neonatal (buccal) and placental (basal plate and parenchyma)16s rRNA with bacteria and 18s rRNA with fungi.

The measurements of cervical length will be performed in two different periods of pregnancy (11-14 and 18-22 weeks of gestation) in singleton pregnancies. Firstly, the vaginal swabs will be collected from women who accept to participate in the study at 11-14th weeks of gestation just before the measurement of cervical length. Also, the vaginal swabs will be done again at 18-22 weeks of gestation as explained above. Micronized progesterone will be started in women with a cervical length equal or less than 25 mm (smaller than 3rd percentile) at 18-22 weeks of gestation. The medication (progesterone 200mg) will be administered intravaginally every night before bedtime and will continue until 36th gestational week unless the patient gives birth. Measurement of cervical length will be repeated transvaginally at 28th and 32nd gestational weeks, and samples will be obtained with a cervical swab before these measurements. In order to evaluate the presence of placental mycobiota and microbiota, 1 cm x 1 cm x 1 cm of the tissue sample from the placenta that is 3 cm lateral of the cord insertion will be taken under sterile conditions after birth. In order to evaluate the amniotic compartment, a buccal mucosal swab will be collected from the neonates immediately after birth. All samples will be delivered to our Research Laboratory immediately and stored in -80 ℃ cabinet until the evaluation. The V3-V4 regions by the 16s ribosomal RNA sequencing method will be sequenced with the Illumina MiSeq device and the data will be analyzed according to the protocols standardized in the Human Microbiome Project.

DNA samples that will be ranked from the data to be sequenced in accordance with the ITS1 region metabiota protocol will be evaluated within the Human Microbiome Project.

Pseudomonas, Escherichia, Neisseria, Streptococcus, Lactobacillus, Candida, Actinomyces will be used as positive controls and, V3-V4 and ITS regions will be matched for bacterial microbiota and Fungal microbiota. After the "Operational taxonomic units" of the amplicons are configured with the VSEARCH program, the analyzes will be carried out with GENBANK microbiota and micobiota data.


Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 92 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 41 Weeks
Official Title: Evaluation of the Relationship Between Vaginal, Placental and Neonatal Mycobiota and Microbiome With Preterm Birth in Women With Short Cervical Length
Estimated Study Start Date : December 1, 2019
Estimated Primary Completion Date : December 1, 2020
Estimated Study Completion Date : December 1, 2022

Group/Cohort Intervention/treatment
Term Birth
Delivery between 37-41 weeks of gestation
Diagnostic Test: Collection of vaginal, neonatal buccal and placental samples
Analysis of microbiome and mycobiota of vaginal, neonatal buccal and placental

Preterm birth
Delivery between 24-37 weeks of gestation
Diagnostic Test: Collection of vaginal, neonatal buccal and placental samples
Analysis of microbiome and mycobiota of vaginal, neonatal buccal and placental




Primary Outcome Measures :
  1. Characterization of Maternal-Fetal microbiome and mycobiome [ Time Frame: 11 weeks of gestation to date of delivery ]
    Characterize the maternal(vaginal), placental, and neonatal (buccal) microbiome and mycobiome in a cohort at risk of preterm birth by using the BIO Power Soil DNA Isolation kit. The investigators will able to evaluate whether there is an association between microbiome and mycobiome changes with preterm birth. The V3-V4 regions by the 16s rRNA and ITS regions by 18s rRNA sequencing method will be sequenced. After the "Operational taxonomic units" of the amplicons are configured with the VSEARCH program, the analyzes will be carried out with GENBANK microbiota and micobiota data.


Secondary Outcome Measures :
  1. The effect of progesterone on maternal microbiome (vaginal and placenta) with progesterone [ Time Frame: 11 weeks of gestation to date of delivery ]
    Characterize the maternal, placental, and neonatal microbiome in a cohort at risk of preterm birth who receive progesterone treatment. Not all the women will ultimately deliver at term despite of prophylactic management of progesterone; the investigators will be able to see if there are microbiome changes associated with preterm birth by using the BIO Power Soil DNA Isolation kit. We will able to evaluate whether there is an association between microbiome and mycobiome changes with preterm birth. The V3-V4 regions by the 16s rRNA and ITS regions by 18s rRNA sequencing method will be sequenced. After the "Operational taxonomic units" of the amplicons are configured with the VSEARCH program, the analyzes will be carried out with GENBANK microbiota and micobiota data.

  2. Variety of microbial and mycobial fingerprintings [ Time Frame: 11 weeks of gestation to date of delivery ]
    Comparison of vaginal, neonatal buccal and placental 16S rRNA and 18S rRNA gene sequencing between women with a short cervix who give a preterm birth with those who deliver at term.


Biospecimen Retention:   Samples With DNA
Maternal (vaginal), neonatal (buccal) and placental specimens will be collected. Genomic DNA will be stored at -80 ℃ until the analysis of microbiota and mycobiota are performed by using BIO PowerSoil DNA isolation kits.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Pregnant women attending prenatal clinics of Koc University Hospital in Istanbul.
Criteria

Inclusion Criteria:

  • Singleton pregnancies
  • The subject has voluntarily signed the Informed Consent Form and associated forms after having the contents explained

Exclusion Criteria:

  • Multiple pregnancies
  • The presence of a major fetal anomaly or known chromosomal abnormality
  • Finding the intrauterine mort de fetus
  • Antibiotic and/or antifungal use within two weeks at the collection of samples
  • Pregnant women under 18 years of age
  • Women with previous cervical surgery
  • Women who do not accept to participate to be in the study
  • The presence of a uterine anomaly
  • Women with vaginal bleeding at the time of cervical swabs taken

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04165252


Contacts
Layout table for location contacts
Contact: Ebru Celik, M.D. +90 850 250 8 250 ext 21654 ecelik@ku.edu.tr

Sponsors and Collaborators
Koç University
Tubitak
Investigators
Layout table for investigator information
Study Director: Ebru Celik, M.D. Koç University
Study Director: Fusun Can, M.D. Koc University School of Medicine
Principal Investigator: Mert Turgal, M.D. Koc University School of Medicine
Principal Investigator: Ozlem Dogan, M.D. Koc University School of Medicine
Principal Investigator: Mehmet Gonen, P.h.D Koc University School of Medicine
Principal Investigator: Tugba Gursoy, M.D. Koc University School of Medicine
  Study Documents (Full-Text)

Documents provided by Koç University:
Study Protocol  [PDF] March 1, 2019


Publications of Results:
Other Publications:

Layout table for additonal information
Responsible Party: Koç University
ClinicalTrials.gov Identifier: NCT04165252     History of Changes
Other Study ID Numbers: 119S463
First Posted: November 15, 2019    Key Record Dates
Last Update Posted: November 15, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The recruitment of participants will begin on November 2019 and the anticipated date for the completion of the study is November 2022.
Supporting Materials: Study Protocol
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Analytic Code
Time Frame: The data will be available for 5 years
Access Criteria: The researchers who are responsible for the recruitment of patients will have access code. The web address will be ready in November 2019 and the researcher will have a personal ID and password to enter the participants' data.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Koç University:
Preterm birth
Microbiota
Mycobiota
Short Cervix
Progesterone
Additional relevant MeSH terms:
Layout table for MeSH terms
Communicable Diseases
Infection
Premature Birth
Obstetric Labor, Premature
Obstetric Labor Complications
Pregnancy Complications